Drug therapy reviews: management of hypothyroidism.
The therapeutic management of hypothyroidism caused by deficient thyroid hormone production is discussed. The therapeutic use of the following thyroid agents is reviewed: levothyroxine sodium, Thyroid USP, thyroglobulin, liotrix, and liothyronine sodium. Myxedema coma, neonatal hypothyroidism, primary hypothyroidism, and secondary and tertiary hypothyroidism are specific hypothyroid states for which drug therapy is discussed. Levothyroxine sodium is the preferred agent because of consistent potency, restoration of normal, constant serum levels of thyroxine (T4) and triiodothyronine (T3) and ease of interpretation of thyroid hormone levels. Other agents, because they contain T3, result in postabsorptive elevated T3 serum concentrations that may cause thyrotoxic symptoms and reduction of T4 levels. This, in turn, may give rise to misleading estimates of thyroid dosage. Patients with the sick euthyroid or low T3 syndromes are not candidates for thyroid hormone therapy.
D001327:Autoimmune Diseases / Q000188:drug therapy; D003128:Coma / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D006980:Hyperthyroidism / Q000628:therapy; D007037:Hypothyroidism / Q000188:drug therapy* / Q000209:etiology; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy; D009230:Myxedema / Q000150:complications / Q000188:drug therapy; D013954:Thyroglobulin / Q000627:therapeutic use; D013962:Thyroid (USP) / Q000627:therapeutic use; D013966:Thyroiditis / Q000188:drug therapy; D013974:Thyroxine / Q000008:administration & dosage / Q000627:therapeutic use; D014284:Triiodothyronine / Q000172:deficiency / Q000627:therapeutic use
D013962:Thyroid (USP); D014284:Triiodothyronine; D013954:Thyroglobulin; D013974:Thyroxine